Avid Bioservices (NASDAQ:CDMO) is a leading contract development and manufacturing organization (CDMO) specializing in the production of biologics for the biotechnology and pharmaceutical industries. Headquartered in Tustin, California, the company leverages more than three decades of experience in cell culture, purification, and analytical testing to deliver comprehensive solutions that help clients advance therapies from early stage development through commercial launch. Since its founding in 1989, Avid has focused on scalable, flexible manufacturing platforms that accommodate a range of molecular modalities, including monoclonal antibodies, recombinant proteins, and other complex biologic products.
The company’s service portfolio encompasses process and analytical development, cGMP manufacturing, and regulatory support tailored to client needs. Avid’s development capabilities include cell line evaluation, upstream process optimization, and downstream purification, while its analytical teams provide method development, stability studies, and release testing. Clients benefit from integrated project management and quality systems designed to streamline technology transfer and ensure compliance with global regulatory authorities, facilitating timely progression through clinical milestones.
Avid Bioservices operates state-of-the-art manufacturing suites equipped for both mammalian cell culture and microbial fermentation, with single-use bioreactors and stainless-steel systems capable of producing batches from preclinical to commercial scale. The company’s facilities adhere to stringent safety and quality standards, supporting products at all stages of clinical development as well as full commercial supply. Avid’s flexible capacity and modular design enable rapid scale-up and technology adjustments to meet evolving client requirements and expedite time to market.
Serving customers across North America, Europe, and Asia, Avid has cultivated strategic partnerships with biotech innovators and established pharmaceutical companies alike. The organization is led by a seasoned executive team with extensive expertise in biologics manufacturing, process development, and regulatory affairs. By combining scientific capabilities with a client-centric approach, Avid Bioservices aims to accelerate the development of life-saving therapies and strengthen its position as a trusted partner in the global biologics supply chain.
